Effect of Gut Microbiome Restoration on Primary Hypertension Via Dietary Intervention
Status:
Not yet recruiting
Trial end date:
2022-09-01
Target enrollment:
Participant gender:
Summary
Mounting preclinical and clinical evidences have proved the optimal role of diets (i.e. DASH
(Dietary Approaches to Stop Hypertension) diet, Mediterranean diet) on BP control and a
causal role of gut microbiota on the pathogenesis of primary hypertension. Dietary changes
appeared to reshape gut microbiota and to ameliorate diseases such as Type 2 Diabetes. A
hypothesis is thus raised that dietary changes can be a potential approach to ameliorate
hypertension via gut microbiome restoration. This pilot study will utilize an innovative
natural dietary formulation (patent ID: CN110250417A), in comparison with classic
antihypertensive treatment (losartan 50mg per day) and usual care (guideline-based patient
education and lifestyle recommendations), to investigate its effect and safety on primary
hypertension treatment, and the underlying mechanisms of gut microbiome restoration.
Phase:
Early Phase 1
Details
Lead Sponsor:
Chinese Academy of Medical Sciences, Fuwai Hospital